The text has been copied to the clipboard
Journal article

The consensus molecular subtypes of colorectal cancer.

  • Guinney J Sage Bionetworks, Seattle, Washington, USA.
  • Dienstmann R Sage Bionetworks, Seattle, Washington, USA.
  • Wang X Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
  • de Reyniès A Ligue Nationale Contre le Cancer, Paris, France.
  • Schlicker A Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
  • Soneson C Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Marisa L Ligue Nationale Contre le Cancer, Paris, France.
  • Roepman P Agendia NV, Amsterdam, the Netherlands.
  • Nyamundanda G Institute of Cancer Research, London, UK.
  • Angelino P Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Bot BM Sage Bionetworks, Seattle, Washington, USA.
  • Morris JS The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Simon IM Agendia NV, Amsterdam, the Netherlands.
  • Gerster S Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Fessler E Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
  • De Sousa E Melo F Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
  • Missiaglia E Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Ramay H Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Barras D Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Homicsko K École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
  • Maru D The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Manyam GC The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Broom B The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Boige V Gustave Roussy, Villejuif, France.
  • Perez-Villamil B Laboratorio de Genomica y Microarrays, Instituto de Investigación Sanitaria San Carlos, Hospital Clinico San Carlos, Madrid, Spain.
  • Laderas T Sage Bionetworks, Seattle, Washington, USA.
  • Salazar R Institut Catala d'Oncologia, L'Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.
  • Gray JW Biomedical Engineering, Oregon Health Sciences University, Portland, Oregon, USA.
  • Hanahan D École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
  • Tabernero J Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bernards R Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
  • Friend SH Sage Bionetworks, Seattle, Washington, USA.
  • Laurent-Puig P Université Paris Descartes, Paris, France.
  • Medema JP Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
  • Sadanandam A Institute of Cancer Research, London, UK.
  • Wessels L Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
  • Delorenzi M Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Kopetz S The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Vermeulen L Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
  • Tejpar S Universitair ziekenhuis Leuven, Leuven, Belgium.
Show more…
  • 2015-10-13
Published in:
  • Nature medicine. - 2015
English Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features: CMS1 (microsatellite instability immune, 14%), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; and CMS4 (mesenchymal, 23%), prominent transforming growth factor-β activation, stromal invasion and angiogenesis. Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity. We consider the CMS groups the most robust classification system currently available for CRC-with clear biological interpretability-and the basis for future clinical stratification and subtype-based targeted interventions.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://sonar.ch/global/documents/190344
Export to…

Statistics

Document views: 111 File downloads:
  • Full-text: 0